Hermes Vector

HealthTrending

Sellas Life Sciences Reports Positive Phase 3 AML Trial Data for GPS Vaccine

Sellas Life Sciences says its Galinpepimut-S vaccine reduced the risk of death by 41% in a pivotal Phase 3 AML trial, with median overall survival of 24.0 months versus 14.7 months for best available treatment.

By Hermes Vector

Checked against 3 sourcesfinance.yahoo.comca.finance.yahoo.comca.investing.com
Illustration for: Sellas Life Sciences Reports Positive Phase 3 AML Trial Data for GPS Vaccine

In brief

  • Sellas Life Sciences' Phase 3 REGAL trial met its primary endpoint for GPS in AML patients.
  • GPS reduced the risk of death by 41% with a hazard ratio of 0.59 and p-value of 0.035.
  • Median overall survival was 24.0 months for GPS versus 14.7 months for best available treatment.
  • The company plans an FDA meeting and a Biologics License Application submission in the first half of 2027.

Sellas Life Sciences Reports Positive Phase 3 AML Trial Data for GPS Vaccine

Sellas Life Sciences Group, Inc. announced positive topline results from the pivotal randomized Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an immunotherapeutic cancer vaccine, in patients with acute myeloid leukemia (AML).

Trial Results

The REGAL trial met its primary endpoint of overall survival, with GPS demonstrating a statistically significant and clinically meaningful improvement compared with investigator's choice of best available treatment (BAT).

  • GPS showed a 41% reduction in the risk of death, with a hazard ratio of 0.59 and a two-sided p-value of 0.035.
  • Median overall survival was 24.0 months among GPS-treated patients versus 14.7 months with BAT.
  • The 126-patient study evaluated GPS as maintenance monotherapy in patients who achieved a second or later complete remission or complete remission with insufficient platelet recovery following second- or later-line salvage therapy and who were ineligible for, or unable to undergo, allogeneic stem cell transplantation.

Safety and Next Steps

GPS was generally well tolerated, with a safety profile consistent with prior clinical experience and no new safety signals identified. Treatment-related adverse events were predominantly mild to moderate, most commonly consisting of local injection site reactions.

The company plans to meet with the U.S. Food and Drug Administration (FDA) while advancing preparations for a Biologics License Application (BLA) submission for GPS. Sellas is eyeing a potential BLA submission in the first half of 2027.

"Given the significant unmet need in this patient population, we look forward to engaging with the FDA to discuss the results and the regulatory path forward, with the goal of making this therapy available to patients as rapidly as possible," CEO Angelos Stergiou said.

Sellas is now conducting further analyses of the results, which will be presented at an upcoming major medical conference and submitted for publication in a peer-reviewed medical journal.


Sources

This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.

The day's checked news, by email

One short email a day with the top stories. Free, and you can unsubscribe in one click.

Or follow for the latest news:

How do you feel about this story?

Comments 0

No comments yet. Start the discussion.

HealthTrending

Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion

Eli Lilly has agreed to acquire privately held Calytrix Bio for up to $1.5 billion in cash, adding a preclinical antibody program for rare blood disorders to its hematology portfolio.

Checked against 3 sourcesca.finance.yahoo.comfinance.biggo.comcitybiz.co

Health

Boots to prescribe medical cannabis via video consultations

Boots is launching SureLeaf, an online medical cannabis service for UK patients aged 25 and over with eligible conditions, following online assessment and video consultation.

Checked against 6 sourcesThe Guardianglobalcosmeticsnews.combusinessofcannabis.com+3 more